

Wednesday October 24, 2018

6:00 – 6:15 pm LB1: Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer's disease dementia

Albert C Lo¹, Cynthia Duggan Evans¹, Michele Mancini¹, Qun Lin, Hong Wang¹, Peng Liu¹, Sergey Shcherbinin¹, Ming Lu², Arnaud Charil¹, Brian A Willis¹, Michael Irizarry³

¹Eli Lilly and Company, Indianapolis, IN, USA ²Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA ³Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ

6:15 – 6:30 pm LB2: TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results

Robert Alexander, MD¹, Daniel K. Burns, PhD², Kathleen A. Welsh-Bohmer, PhD³, Carl Chiang, PhD², Meredith Culp, BS⁴, Janet O'Neil, MBA⁴, Brenda L. Plassman, PhD³, Craig Metz, PhD², Deborah Yarbrough, MS, MBA⁴, Jingtao Wu, PhD¹, Rebecca Evans, MD¹, Kumar Budur, MD⁴, Stephen K. Brannan, MD⁴, Ann M. Saunders, PhD², Emiliangelo Ratti, PhD¹; for the TOMMORROW Study Investigators

¹Takeda Development Center Americas, Inc., Cambridge, MA – USA ²Zinfandel Pharmaceuticals, Inc., Durham, NC – USA ³Duke University Bryan ADRC, Durham, NC – USA ⁴Takeda Development Center Americas, Inc., Deerfield, IL – USA

Thursday, October 25, 2018

2:00 – 2:15pm LB3: Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer's disease

Bjørn Sperling, MD¹, Lars Østergaard Pedersen, PhD¹, Neli Boneva, MD¹, Dorthe Daugaard, MD¹, Yudong Zhao, PhD¹

¹ H. Lundbeck A/S, Valby, Denmark

2:15 – 2:30pm LB 4: Predictors of [¹⁸F]flortaucipir (tau) load in Alzheimer's disease and other neurodegenerative disorders

Oskar Hansson, MD, PhD^{1,2}; Gil D. Rabinovici MD, PhD³; Chul H. Lyoo, MD, PhD⁴ & Rik Ossenkoppele, PhD^{1,5}

¹Lund University, Clinical Memory Research Unit, Lund, Sweden, ²Memory Clinic, Skåne University Hospital, Malmö, Sweden, ³Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, ⁴Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ⁵VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands.

Friday, October 26, 2018

11:00 – 11:30 am LB5: ¹⁸F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology

Mark A. Mintun^{1,2}, Adam S. Fleisher², Michael D. Devous², Ming Lu², Anupa K. Arora², Thomas G. Beach³, Thomas J. Montine⁴, Michael J. Pontecorvo²

¹Eli Lilly and Company, Indianapolis, IN, USA ²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA ³Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA ⁴Department of Pathology, Stanford University, Stanford, CA, USA

2:45 – 3:00pm LB6: Age and ApoE genotype-specific population frequencies of cerebral β -amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO

Hany Rofael, MD, PhD¹, Gerald Novak MD¹, Luc Bracoud MSc², Nandini Raghavan PhD¹, Ziad Saad PhD³, S Einstein MS¹, Robert Brashear¹, David Scott PhD⁴, Joel Schaerer PhD², Celeste de Jager PhD⁵, Chi Udeh-Momoh PhD⁵, the Alzheimer's Disease Neuroimaging Initiative (ADNI), and Lefkos Middleton MD⁵.

3:00 – 3:15pm LB7: Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer's disease

Marwan Sabbagh, MD¹, Imogene Dunn, PhD², Ann Gooch, PhD², Tom Soeder, MS³, Karl Kiebertz, MD, MPH⁴, Carmen Valcarce, PhD², Larry D Altstiel, MD, PhD^{2*}, Aaron H Burstein, PharmD²
¹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA ²vTv Therapeutics LLC, High Point, NC, USA ³Cato Research LTD, Durham, NC, USA ⁴Clintrex LLC, Longboat Key, FL, USA

3:15 – 3:30pm LB8: Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer's disease

Samantha Budd Haerberlein, PhD¹, Carmen Castrillo-Viguera, MD¹, Tianle Chen, PhD¹, John O'Gorman, PhD¹, Raj Rajagovindan, PhD¹, Dakshaben Patel, PhD² Philipp von Rosenstiel, MD¹, Guanfang Wang, PhD³, Spyros Chalkias, MD¹, LeAnne Skordos PharmD¹, Claudia Prada, MD¹, Christoph Hock, MD⁴, Roger M Nitsch, MD⁴, Alfred Sandrock, MD, PhD¹
¹Biogen, Cambridge, MA, USA ²Biogen, Maidenhead, UK ³Cytel, Cambridge, MA, USA ⁴Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

3:30 – 3:45pm LB9: Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer's Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers

Harald Hampel, MD, PhD¹, Mohammad Afshar, MD, PhD², Frédéric Parmentier, PhD², Coralie Williams, MSc², Adrien Etcheto, MSc², Federico Goodsaid, PhD³, Christopher U Missling, PhD⁴;
¹Department of Neurology, Sorbonne University, Paris, France, ²Ariana Pharma, Paris, France, ³Regulatory Pathfinders LLC, San Francisco, CA, ⁴Anavex Life Sciences Corp., New York, NY

3:45 – 4:00 pm LB10: Predictive performance of CSF and imaging AD biomarkers in ADNI1/GO/2 MCI participants using the NIA-AA research framework.

Leslie M Shaw, PhD¹, Michal Figurski, PhD¹, Susan Landau, PhD², William Jagust, MD², Clifford R Jack, MD³, Paul S Aisen, MD⁴, Ronald C Petersen, MD³, Michael W Weiner, MD⁵, John Q Trojanowski, MD, PhD¹
¹University of Pennsylvania, Philadelphia – USA ²University of California, Berkeley, Berkeley – USA ³Mayo Clinic, Rochester – USA ⁴University of Southern California, San Diego – USA ⁵University of California, San Francisco – San Francisco – USA